Foundation Fighting Blindness: ViGeneron Receives FDA Authorization to Launch Clinical Trial for MRNA Trans-Splicing Gene Therapy for Stargardt Disease
December 21, 2024
December 21, 2024
COLUMBIA, Maryland, Dec. 21 -- The Foundation Fighting Blindness issued the following news:
* * *
The company is also planning to conduct the clinical trial at sites in the EU.
* * *
ViGeneron, a company developing genetic therapies for eye diseases, has received authorization from the US Food & Drug Administration (FDA) to launch a Phase 1/2 clinical trial for VG801, an emerging mRNA trans-splicing gene therapy for people with Stargardt di . . .
* * *
The company is also planning to conduct the clinical trial at sites in the EU.
* * *
ViGeneron, a company developing genetic therapies for eye diseases, has received authorization from the US Food & Drug Administration (FDA) to launch a Phase 1/2 clinical trial for VG801, an emerging mRNA trans-splicing gene therapy for people with Stargardt di . . .